User login

Levin Says 'May 10' Applies To Biologics, Signals Opposition To '5+3'

October 2, 2015 at 3:12 PM
ATLANTA -- House Ways & Means Committee Ranking Member Sander Levin (D-MI) on Friday (Oct. 2) strongly signaled that he opposes the new U.S. proposal for an eight-year market exclusivity term for biologics drugs in the Trans-Pacific Partnership (TPP) because it goes beyond the so-called “May 10” agreement that he negotiated with the George W. Bush administration. Levin argued that the May 10 deal provided for five years of data exclusivity for all drugs, including biologics. “As it's discussed, I...

Not a subscriber? You can request 30 days free access to exclusive, behind-the-scenes reporting on trade policy in the Biden era.